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Background: Recent studies suggest that viral interleukin 10 suppresses alloim-
mune response in transplantation and that cationic lipids are one of the most
promising nonviral vehicles for gene therapy. The aim of this study was to examine
the effect of ex vivo lipid-mediated viral IL10 gene transfer into rat lung allografts
on subsequent rejection.
Methods: Male F344 rats (RT1lvl) underwent left lung transplantation with allo-
grafts from Brown Norway rats (RT1n). Allografts were transvascularly transfected
15 minutes after harvest with 5 mL of 1:20-diluted (group 1, n = 7) or 1:40-diluted
(group 2, n = 6) GL67-pCMVievIL-10 complex. Group 3 (n = 7), serving as the
control group, received 1:40-diluted GL67-pCF1-chloramphenicol acetyltrans-
ferase complex. All allografts were preserved for 3 hours at 10°C before transplan-
tation. In all groups recipients were killed on postoperative day 5. Transgene
expression of viral interleukin 10 was assessed by means of both reverse transcrip-
tase–polymerase chain reaction and immunohistochemistry. Histologic rejection
score, allograft gas exchange, exhaled nitric oxide level, and allograft cytokine
mRNA expression were also assessed.
Results: Dose-dependent transgene expression of viral interleukin 10 was detect-
ed by means of both reverse transcriptase–polymerase chain reaction and
immunohistochemistry. Allograft gas exchange (PaO2) in groups 1 (114.06 ±
61.1 mm Hg) and 2 (108.58 ± 35.7 mm Hg) was significantly better than that in
group 3 (66.4 ± 8.22 mm Hg; P = .020 and P = .023, respectively). The vascular
rejection score in group 1 was significantly lower than that in group 3 (P = .032,
Kruskal-Wallis test). Exhaled nitric oxide levels in group 2 (5.150 ± 6.38 ppb)
were significantly lower than those in group 3 (13.517 ± 10.4 ppb; P = .039).
Allograft interleukin 2 mRNA expression levels in group 1 (1.123 ± 0.23 relative
units) were significantly lower than those in group 3 (1.753 ± 0.71 relative units;
P = .038 vs group 3).
Conclusions: Lipid-mediated ex vivo viral IL10 gene transfer into rat lung allografts
improved graft gas exchange, reduced histologic rejection scores, downregulated
graft interleukin 2 mRNA expression, and reduced exhaled nitric oxide levels by
postoperative day 5. These results suggest a therapeutic potential of graft viral IL10
gene transfer as an effective immunosuppressive strategy against lung allograft
rejection.
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Lung transplantation has evolved into an effec-tive therapeutic option in the management ofpatients with end-stage pulmonary diseases.1However, allograft rejection remains a seriousimpediment to the clinical success of lungtransplantation. Gene transfer, the temporary
introduction of genes to organs, which results in transient gene
expression and production of a functional gene product to
modify tissue responses, might be an effective strategy to
decrease transplant rejection. Ex vivo gene delivery to grafts
during cold storage before implantation might offer a specific
opportunity for achieving graft-targeted, sustained, endoge-
nous production of therapeutic gene products, while at the
same time minimizing possible unwanted exposure to the
transgene product of nontargeted organs. Gene transfer of
immunosuppressive cytokine genes to the allograft may be a
viable local immunosuppressive strategy by markedly impair-
ing effective antigen presentation, reducing or eliminating
immunogenicity, and preventing rejection or prolonging graft
survival while avoiding the systemic toxicity of conventional
immunosuppression.
Interleukin 10 (IL-10) is mainly produced by macrophages
and TH2 cells. It inhibits the synthesis of cytokines by TH1
cells activated by monocyte/macrophage antigen-presenting
cells.2 It has been shown that IL-10 inhibits
monocyte/macrophage–dependent T-cell activation and anti-
gen presentation,3,4 as well as alloreactivity in vivo.5 Because
of these effects, it has been suggested that IL-10 might be use-
ful in the prevention of transplant rejection. Stimulatory
effects of IL-10, however, have also been observed on both T-
and B-cell differentiation, including enhancing major histo-
compatibility complex (MHC) class II expression on B cells.
Viral IL-10 (vIL-10), a product encoded by the Epstein-Barr
virus BCRF1 open-reading frame, is homologous to cellular
IL-10, especially in the coding region of the mature protein
sequence.6 It shares many biologic properties with cellular IL-
10, including cytokine synthesis inhibitory activity and down-
regulation of class II MHC expression on monocytes. vIL-10,
however, does not possess such costimulatory activities of cel-
lular IL-10,7 which suggests that vIL-10 may be a more potent
immunosuppressant molecule.
In the current study we examined the influence of lipid-
mediated viral IL10 gene transfer and overexpression with-
in lung allografts on subsequent rejection in an MHC-mis-
matched strain combination.
Material and Methods
Plasmids
The plasmids pCMVievIL-10 and pCF1-chloramphenicol acetyl-
transferase (CAT) were kindly provided by Genzyme Corporation
(Framingham, Mass). pCMVievIL-10 was constructed to encode
the immunosuppressive cytokine vIL-10 under the control of the
human cytomegalovirus immediate early promoter in the sense ori-
entation. pCF1-CAT consists of the human cytomegalovirus imme-
diate early gene promoter-enhancer CAT cDNA, as previously
described.8 The sequence of vIL-10 was confirmed by DNA
sequencing before use with the 377 DNA Sequencer (PE Applied
Biosynthesis, Foster City, Calif). The bioactivity of pCMVievIL-
10 was confirmed by the in vitro functional assay, as reported pre-
viously,9 on the basis of the ability of IL-10 to inhibit the synthe-
sis of interferon (IFN) γ by phytohemagglutinin antigen
P–stimulated human peripheral blood mononuclear cells.6
Liposomal Vector
Genzyme lipid 67 (Genzyme Corporation) is an amphiphile con-
sisting of a hydrophobic lipid anchor group (cholesterol) linked to
a positively charged spermine head group in a T-shaped configura-
tion. Lipid 67/dioleylphosphatidylethanolamine in a molar ratio of
1:2 was supplied as dried films and kept at 80°C, as previously
described.8 The dried lipid films were hydrated with sterile 4°C
water, treated in a vortex, and kept at 4°C for 10 minutes. This
homogeneous suspension was mixed with an equal volume of plas-
mid DNA and kept at 30°C for 15 minutes. The final concentra-
tions were 1 mmol/L for the cationic lipid mixture and 4 mmol/L
for the plasmid DNA. Immediately before the injection to the allo-
grafts, the complex solution was diluted into 5 mL of saline solu-
tion in a 1:20 or 1:40 ratio.
Animals
Male inbred Brown Norway and F344 rats, weighing 250 to 320 g,
were obtained from Harlan Sprague-Dawley (Indianapolis, Ind).
All animal procedures were approved by the Animal Study
Committee of Washington University. Animals received humane
care in compliance with the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996.
Study Design, Gene Transfer, and Transplantation
Animals were divided into 3 groups. Transfection was accom-
plished with 5 mL of 1:20-diluted (group 1, n = 7) or 1:40-diluted
(group 2, n = 6) GL67-pCMVievIL-10 complex. Group 3 (n = 7),
serving as the control group, received 1:40-diluted GL67-pCF1-
CAT complex. Donor rat pulmonary arteries were flushed with 20
mL of cold (4°C) saline solution after systemic heparinization.
Heart-lung blocks were immediately excised en bloc and kept at
10°C. The GL67-plasmid complex diluted in 5 mL of saline solu-
tion was injected into the allograft pulmonary vein retrograde
through a 20-cm polyethylene tube (internal diameter 0.38 mm),
with a pressure of 20 cm H20 for 10 minutes. After storage in
saline solution at 10°C for 3 hours, the grafts were flushed with
cold (4°C) saline solution to eliminate the remaining liposome-
DNA complexes from the pulmonary vasculature. Left lung allo-
grafts were then orthotopically transplanted by means of a modifi-
cation of the previously described cuff technique.10
Assessment
Recipient animals underwent median sternotomy on postoperative
day 5. After crossclamping of the right main bronchus and pul-
monary artery, allografts were ventilated with 100% oxygen (1.5
mL of tidal volume at a rate of 100 breaths/min). Peak airway pres-
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sures were measured, and exhaled gas was collected for 3 minutes.
After 5 minutes of graft ventilation, arterial blood samples were
obtained for blood gas analysis. Recipients were then killed, and
left lung allografts were immediately flushed with 20 mL of cold
saline solution. The lower half of the lung graft was frozen in liq-
uid nitrogen and stored at –80°C for reverse transcriptase–poly-
merase chain reaction (RT-PCR) assessment. The upper half of the
graft was fixed with Histochoice fixative (AMRESCO, Solon,
Ohio) flushed through the trachea with 20 cm H20 for histologic
assessment. These sections were stained with hematoxylin and
eosin and examined by a pathologist (J.H.R.) blinded to the tissue
group. The sections were graded separately for both acute vascular
rejection and airway rejection on the basis of the revised working
formulation, as described previously.11
RNA Isolation and cDNA Synthesis
Total lung RNA was prepared by means of guanidine isothio-
cyanate extraction with RNeasy Mini Kit (QIAGEN Inc,
Valencia, Calif), according to the manufacturer’s instructions.
Extracted RNA was quantified by a spectrophotometer
(Spectronic Genesys 5; Spectronic Instruments, Inc, Rochester,
NY). Each microgram of extracted RNA was reverse transcribed
at room temperature for 10 minutes, 42°C for 15 minutes, 99°C
for 5 minutes, and 5°C for 5 minutes in a total of 20 µL of reac-
tion mixture: 5 mmol/L MgCl2; 50 mmol/L KCl; 10 mmol/L
Tris-HCl (pH 8.3); 1 mmol/L of each deoxynucleotide triphos-
phate, 1 µL of RNase inhibitor, 2.5 U/µL cloned murine
leukemia virus reverse transcriptase, and 2.5 µmol/L oligo
d(T)16 (Perkin Elmer, Foster City, Calif).
Semiquantitative PCR
Reverse-transcribed cDNA was amplified by PCR with 0.01 to
0.03 U/µL Hot StarTaq Polymerase (QIAGEN Inc, Valencia, Calif)
on a Mastercycler gradient (Eppendorf Scientific, Hamburg,
Germany) in a 22-µL reaction (2.0 µL of RT product, 1.5 mmol/L
MgCl2, 200 µmol/L of each deoxynucleotide triphosphate, and 0.3
to 0.5 µmol/L of each primer, PCR buffer [QIAGEN Inc, Valencia,
Calif]), including KCl, Tris-HCl, and (NH4)2SO4, after the first
step of 95°C for 17 minutes, 25 to 35 cycles at 95°C for 30 sec-
onds, 58°C (annealing temperature varying for different primers)
for 30 seconds, and 72°C for 1 minute, followed by a final incuba-
tion at 72°C for 10 minutes. The sense and antisense sequence of
primer pairs was designed for glyceraldehyde-3-phosphate dehy-
drogenase, vIL-10, IL-2, tumor necrosis factor α, inducible nitric
oxide synthase (iNOS), IFN-γ, and endogenous IL-10.
PCR cycles and annealing temperature were calibrated for each
primer pair. The glyceraldehyde-3-phosphate dehydrogenase
bands were used to calibrate PCR input at unsaturated amplifica-
tion for semiquantification. PCR products were electrophoresed on
a 0.8% agarose gel and visualized by means of ethidium bromide
staining. The gel images were stored by using the Gel
Documentation System Image Store 7500 (version 7.12; UVP Inc,
Upland, Calif) with a UV transilluminator. The average optical
density of bands was quantitated by using the GelBase/GelBlot-
Pro software (version 3.10; Syngene/Synoptics Ltd, Frederick,
Md). Normal left lung samples of Brown Norway rats (n = 6) were
also assayed in the same way as samples from the other groups for
comparison.
Immunohistochemistry for vIL-10
Paraffin-embedded lung allograft sections were mounted on
charged glass slides. After deparaffinization and hydration in grad-
ed ethanol, antigen retrieval was performed by means of steam
treatment in Target Retrieval Solution (DAKO, Carpinteria, Calif)
for 35 minutes at 95°C. Blocking steps included Fc Receptor
Blocker (Accurate Chemical & Scientific Corp, Westbury, NY)
and Super Block Blocking Buffer (PIERCE, Rockford, Ill) supple-
mented with 10% normal goat serum and 1% bovine serum albu-
min. All washes consisted of TBS (100 mmol/L Tris and 500
mmol/L NaCl, pH 7.4) supplemented with 0.1% saponin and 0.2%
Triton X-100, by using the R&D Systems (Minneapolis, Minn)
permeabilization protocol for cytokines.The immunohistochem-
istry procedure was enhanced with the Tyramide Signal
Amplification kit (TSA-Indirect; NEN Life Science Products,
Boston, Mass), according to the manufacturer’s instructions. All
steps were performed at room temperature. In brief, the slides were
incubated overnight with biotinylated rat antiviral IL-10 mAb
(1:25; Pharmingen, San Diego, Calif). After quenching endoge-
nous peroxidase with 3% H2O2/phosphate-buffered saline solution
for 15 minutes, the slides were incubated with streptavidin-horse-
radish peroxidase for 30 minutes, biotinyl tyramide solution for 25
minutes, and streptavidin-alkaline phosphatase for 30 minutes.
Color development was performed with BCIP/NBT substrate
(Vector Laboratories, Inc, Burlingame, Calif), including le-
vamisole, 5 mmol/L. Slides were counterstained with nuclear fast
red and permanently mounted with Cytoseal 60 (Stephens
Scientific, Kalamazoo, Mich).
Exhaled Nitric Oxide Analysis
Nitric oxide (NO) levels in allograft exhaled gas were measured
with a Sievers 280 NO analyzer (Sievers Instruments, Inc, Boulder,
Colo) within 30 minutes of collection. Emissions from electroni-
cally excited nitrogen dioxide were detected in a gas-phase chemi-
luminescent reaction between NO and ozone. The sensitivity of the
measurement is less than 1 ppb. At every measurement, it was con-
firmed that the baseline NO level of 100% oxygen was 0 ppb.
Exhaled NO from normal left lungs of Brown Norway rats (n = 5)
was also measured in the same way as that for the other study
groups.
Statistical Analysis
Data were analyzed by means of 1-way analysis of variance and
the Fisher post hoc multiple comparison test. Data not normally
distributed were transformed with a square root or logarithmic
transformation before performing the analysis of variance.
Nonparametric data were analyzed with the Kruskal-Wallis test
and the Mann-Whitney test with Bonferroni correction. All data
are expressed as means ± SD.
Results
Semiquantitative RT-PCR for Transgene vIL-10
Semiquantitative RT-PCR for vIL-10 was performed to con-
firm allograft pCMVievIL-10 transfection at transcriptional
levels. vIL-10 transgene mRNA expression in lung grafts was
detected in all samples of groups 1 and 2. No vIL-10 mRNA
was detected in group 3 (Figure 1). vIL-10 transgene mRNA
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expression (mean ± SD) in group 1 (2.33 ± 1.44 relative units)
was significantly higher than that in group 2 (0.637 ± 0.74 rel-
ative units; P = .005). These results confirmed the presence of
transgene vIL-10 expression in all lung allografts of groups 1
and 2 in a dose-dependent fashion.
Immunohistochemistry for Transgene vIL-10
Immunohistochemistry for vIL-10 was performed with sec-
tions prepared from paraffin-embedded tissues to confirm
allograft pCMVievIL-10 transfection at translational levels.
There was strong cytoplasmic staining in the majority of
bronchial epithelial cells. No nuclear staining was observed.
Positive staining in alveolar epithelial cells was also
observed in both flattened type I cells and hub-like type II
cells. The staining was more focal and was seen in approx-
imately 25% of the alveolar epithelial cells. Alveolar
macrophages also showed positivity in the cytoplasm. No
staining was observed in endothelial cells, stromal cells, or
lymphocytes within the perivascular cuffs (Figure 2). These
findings demonstrate vIL-10 transfection to specific types
of cells and local production of vIL-10 transgene protein
within allografts. The staining was specific to transgene
vIL-10 because we did not see any staining in group 3.
Histologic Rejection Score
The vascular rejection score in group 1 was significantly
lower than that in group 3 (P = .032, Kruskal-Wallis test).
There were no significant differences between groups in
histologic airway rejection grading (Figure 3). These results
suggest that allograft vIL-10 overexpression could lead to
major immunoalteration to the point at which histologic dif-
ferences can be seen and lung allograft rejection is reduced.
Lung Graft Function
PaO2 (mean ± SD) levels in arterial blood obtained 5 min-
utes after right hilar crossclamping in groups 1 (114.06 ±
61.1 mm Hg) and 2 (108.58 ± 35.7 mm Hg) were signifi-
cantly higher than those in group 3 (66.40 ± 8.22 mm Hg; 
Figure 1. Semiquantitative RT-PCR analysis of vIL-10 mRNA transgene expression in rat lung allografts. The peak
areas of bands were expressed as a relative ratio of vIL-10/glyceraldehyde-3-phosphate dehydrogenase
(GA3PDH). The gel image shows vIL-10 bands from groups 1 and 2 but not from group 3. The relative ratio of vIL-
10/glyceraldehyde-3-phosphate dehydrogenase in group 1 was significantly higher than that in group 2 (P = .0050
vs group 2). Values are means ± SD of 6 or 7 animals per group. PC, Positive control.
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P = .020 and P = .023, respectively, vs group 3; Figure 4).
There were no significant differences between groups in
PaCO2 levels (P = .82) and peak airway pressures (P = .64).
These data show that graft vIL-10 overexpression signifi-
cantly improved graft lung function, suggesting the allevia-
tion of allograft rejection.
Exhaled NO Levels
Exhaled NO levels (mean ± SD) in group 2 (5.150 ± 6.38
ppb) were significantly lower than those in group 3 (13.517
± 10.4 ppb; P = .039 vs group 3), whereas exhaled NO lev-
els from normal left lungs of Brown Norway rats (0.00 ±
0.00 ppb) were significantly lower than those in groups 1
and 3 (P < .005, respectively). There were no significant dif-
ferences between groups 1 and 3 (P = .49, Figure 5). These
results indicate that local vIL-10 overexpression with only
low-dose pDNA-lipid complex significantly suppresses
exhaled NO levels. The results suggest that exhaled NO lev-
els in normal lungs are low (and not detectable in this
model) and that the upregulated exhaled NO levels in allo-
graft rejection can be remarkably suppressed by graft vIL-
10 overexpression.
Semiquantitative RT-PCR for Allograft Cytokine
Expression
Allograft IL-2 mRNA expression levels (mean ± SD) in
group 1 (1.123 ± 0.23 relative units) were significantly
lower than those in group 3 (1.753 ± 0.71 relative units; P =
.038 vs group 3), whereas IL-2 expression levels in group 2
(1.181 ± 0.74 relative units) were also lower than those in
group 3, trending toward the significant level (P = .068 vs
group 3). Normal lung IL-2 expression levels (0.666 ± 0.23
relative units) were significantly lower than those in group 3
(P = .0014 vs group 3, Figure 6). These results suggest that
Figure 2. Immunohistochemistry for transgene vIL-10. Transgene vIL-10 protein was detected by means of immuno-
histochemistry in bronchial endothelial cells, alveolar epithelial cells, and alveolar macrophages. (Original mag-
nifications: A, 200×; B, 200×; C, 400×; D, 400×.)
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IL-2 mRNA expression levels are low in normal lungs and
significantly upregulated during allograft rejection by day 5.
Furthermore, our data indicated that allograft IL-2 upregu-
lation is significantly reduced by local vIL-10 overexpres-
sion.
Normal lung mRNA expression of tumor necrosis factor
α, iNOS, IFN-γ, and endogenous IL-10 was also signifi-
cantly lower than that in other groups (P < .05, respective-
ly), although no significant differences were observed
between groups 1 and 3 or groups 2 and 3 (Figure 7). These
findings suggest that mRNA expression of these cytokines
was minimal in normal lungs and remarkably upregulated
during allograft rejection by postoperative day 5. However,
graft vIL-10 overexpression in this model did not lead to
any significant change in graft cytokine levels.
Discussion
The present results demonstrated that lipid-mediated ex vivo
viral IL10 gene transfer into rat lung allografts improved
graft gas exchange, reduced histologic rejection scores,
downregulated graft IL-2 mRNA expression, and reduced
exhaled NO levels on post-transplantation day 5 in a model
of BN-to-F344 lung allotransplantation. Several other stud-
ies have indicated that local vIL-10 production can suppress
Figure 3. Histologic rejection score. The sections were graded
separately for both acute vascular rejection (A-score) and airway
rejection (B-score). The acute vascular rejection score in group 1
was significantly lower than that in group 3 (P = .042 vs group 3,
Kruskal-Wallis test). There were no significant differences (NS) in
airway rejection scores. Bars show median values.
Figure 4. Arterial blood oxygen tension (PaO2). PaO2 obtained 5
minutes after right hilar crossclamping is shown. Each PaO2 in
groups 1 (114.06 ± 61.05 mm Hg) and 2 (108.58 ± 35.7 mm Hg) was
significantly higher than that in group 3 (66.4 ± 8.22 mm Hg; P = .020
and P = .023 vs group 3). Values are means ± SD of 6 or 7 animals
per group.
Figure 5. Exhaled NO levels from rat lung allografts. Exhaled NO
levels in group 2 (5.150 ± 6.38 ppb) were significantly lower than
those in group 3 (13.517 ± 10.4 ppb; P = .020 vs group 3). Exhaled NO
levels in normal lungs (NL; 0.00 ± 0.0 ppb) were significantly lower
than those in groups 1 and 3 (*P < .005, respectively). Values are
means ± SD of 5 to 7 animals per group.
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immune reactivity in response to alloantigen. Although
some reports indicated detrimental effects12 or ineffective-
ness13 of cellular IL-10, which possesses immunostimulato-
ry activities on allograft rejection, retroviral or lipid-mediat-
ed gene transduction of vIL-10 prolonged graft survival
when injected directly into cardiac allografts.14,15 Viral IL10
gene transfer also decreased allogenic lymphocyte prolifer-
ative response to cultured human islets.16 Consistent with
these observations, the present data seem to show the sig-
nificant efficacy of graft ex vivo viral IL10 gene transfer as
a strategy for local lung-graft alloimmune suppression.
A diverse range of delivery vehicles is currently being
assessed to facilitate gene transduction. These include
recombinant replication-deficient viral vectors and cationic
lipids, and both delivery systems possess certain advantages
and disadvantages. Although adenovirus-mediated gene
transfer is significantly more efficient than that afforded by
cationic lipids,8 the recombinant viruses can be prone to
inflammation and inactivation by the host immune sys-
tem.17 Cationic lipids, one of the most promising nonviral
vehicles,18 are less immunostimulatory. They are invariably
composed of a hydrophobic lipid anchor group capable of
forming liposomes and interacting with membranes linked
to a positively charged head group that interacts with and
perhaps condenses the pDNA. DNA-cationic lipid complex-
es also possess dose-dependent toxicity, especially when
directly delivered to the lungs, which can be attributed to the
detergent-like activity of the cationic lipid component19 or
the immunostimulatory unmethylated CpG sequences har-
bored in plasmid DNA.20 Cationic lipids facilitate gene
transfer through still poorly understood processes. This
involves formation of a positively charged DNA-cationic
lipid complex, adherence to the negatively charged cell
membrane, endocytosis of the complex, release of DNA
from the endosome into the cytoplasm, and translocation of
DNA into the nucleus, leading to eventual gene expres-
sion.21 Optimized formulation of GL67 has been shown to
be highly efficient and relatively less toxic for gene transfer
Figure 6. Semiquantitative RT-PCR analysis of IL-2 mRNA expression in rat lung allografts. The peak areas of the
bands were expressed as the relative ratio of IL-2/glyceraldehyde-3-phosphate dehydrogenase (GA3PDH). IL-2
mRNA expression in group 1 and in normal lungs was significantly lower than that in group 3 (P = .039 and P =
.0014 vs group 3). IL-2 mRNA expression in group 2 was lower than that in group 3, trending toward significance
(P = .068 vs group 3). Values are means ± SD of 6 or 7 animals per group.
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to the lung and 100 times more active than the early gener-
ation cationic lipid.8 Our prior study of naked viral IL10
gene transfer with a BN-to-Lewis lung allograft rejection
model could not exert substantial reduction of rejection,
except for decreased graft expression of iNOS mRNA and
suppression of exhaled NO9. The present GL67-mediated
vIL-10 transfection attenuated allograft rejection, which
may be attributable to the enhanced transfection efficiency
of GL67 in comparison with DNA administered alone.22
In the current study the ex vivo GL67-mediated approach
was used for a graft-targeted viral IL10 gene transfer. Our
prior work on this method of gene transfer has suggested
that gene transfer at low temperatures during graft storage
yielded consistent and reproducible transgene expression,
even with short storage times.23 With storage at 10°C for 1
hour, transgene CAT expression became detectable 4 to 6
hours after implantation, and significant levels were
observed for at least 28 days. We and others have shown that
lung allografts are rejected rapidly, between 4 and 6 days
after transplantation in such an RT1-incompatible donor-
recipient combination as BN to F344.24,25 Thus, we expect-
ed that fulminant rejection would be present in control
recipients if animals were killed on postoperative day 5 and
that transgene expression might be achieved before the time
of alloimmune reaction. Another study in our laboratory
using the same approach also suggested that the optimum
concentration of lipid-DNA complex is 100 or 200 µmol/L
DNA for transfection without pulmonary toxicity.26 On the
basis of these findings, we used the current concentration of
lipid 67-DNA complex, storage temperature, and time.
In the current study allograft vIL-10 overexpression sig-
nificantly suppressed intragraft IL-2 mRNA upregulation.
In the rejection process IL-2, produced by activated T cells,
promotes proliferation of T cells, leading to destruction of
the allograft. Substantial evidence both from experimental
and clinical studies has shown that IL-2 upregulation is
Figure 7. RT-PCR analysis for mRNA expression of tumor necrosis factor (TNF) α, iNOS, IFN-γ, and endogenous IL-
10 in rat lung allografts. Normal lung (NL) mRNA expression in these cytokines was significantly lower than that
in other groups (*P < .05, respectively). There were no significant differences between groups 1, 2, and 3. Values
are means ± SD of 4 to 7 animals per group. GA3PDH, Glyceraldehyde-3-phosphate dehydrogenase.
Itano et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery  •  Volume 122, Number 1 37
TX
ET
CS
P
A
CD
G
TS
G
TS
ED
IT
O
RI
A
L
associated with allograft rejection. Studies evaluating IL-2
mRNA from biopsy specimens in clinical cardiac trans-
plants have demonstrated a strong association between IL-2
expression and histologic rejection.27,28 A number of
immunosuppressive treatments, resulting in decreased pro-
duction of IL-2 by graft-infiltrating cells, also allow prolon-
gation of organ allografts.29 It has been reported that IL-10
directly inhibits human T-cell proliferation by specifically
inhibiting IL-2 production at the transcriptional level when
these cells are activated in an antigen-presenting, cell-inde-
pendent manner.30 This is a direct effect of IL-10 on T cells
mediated by their constitutively expressed IL-10 receptor.31
Florquin and colleagues32 have also shown that endogenous
IL-10 induced by staphylococcal enterotoxin B in CD4+
cells plays a cell-dependent immunoregulatory role in a
model of T cell–dependent shock by downregulating IL-2
and IFN-γ production. Put into the context of these studies,
the present findings of significant suppression of intragraft
IL-2 expression by vIL-10 suggest that reduced rejection
can at least in part be attributed to the IL-2–suppressive
effect of vIL-10.
The present results demonstrated the upregulation of
exhaled NO levels in rejected allografts. We also observed
suppression of exhaled NO levels with low-dose pDNA-
lipid complex but without suppression of iNOS mRNA on
histologic allograft rejection. High-dose pDNA-lipid com-
plex did not suppress exhaled NO levels but reduced the his-
tologic allograft rejection. The exhaled NO level has
become increasingly recognized as a noninvasive marker of
acute lung allograft rejection.33 Upregulation of iNOS
mRNA expression and increased production of NOS and
NO during allograft rejection have been also demonstrated
in many experimental and clinical transplantations,25,34
whereas increased immunosuppressive therapy has been
able to restore these to normal levels.35 Our prior study of
naked viral IL10 gene transfer with a BN-to-Lewis lung
allograft rejection model demonstrated a direct correlation
between high exhaled NO levels from rejected lungs and
iNOS mRNA upregulation.9 In the current study, however,
the effects of vIL-10 on allograft iNOS expression levels
were not clear, and there was no positive correlation
between these 2 parameters on postoperative day 5, despite
significantly suppressed exhaled NO levels with low-dose
pDNA-lipid complex. These results may be attributed to the
proinflammatory properties of liposome GL67/unmethylat-
ed pDNA complex, which can promote proinflammatory
cytokine expression in a dose-dependent fashion,20 includ-
ing IFN-γ. Given that exhaled NO levels reflect both iNOS
upregulation and the net allograft rejection, as shown in
above-mentioned studies, the present data may still support
the notion that the vIL-10 immunosuppressive activity par-
allels iNOS/exhaled NO levels in acute lung rejection,
whereas its suppressive effect on iNOS expression was
obscured by proinflammatory properties of pDNA-lipid
complex in a dose-dependent fashion.
This study has a number of potential limitations. Results
might be different with alternate doses of plasmid or lipid
vector. However, as noted above, these doses were selected
after careful review of our own preliminary data and data
from other reports. The ex vivo route of administration has
proven effective, especially when transgene expression is
not required at the time of transplantation. In addition, it is
recognized that no matter how effective, gene transfer
results in only temporary transgene expression. In this study
the 5-day kill time was selected because in this major anti-
genic mismatch combination fulminant rejection with graft
loss in untreated animals is known to occur 5 days after
transplantation. Our hope was to affect this fulminant rejec-
tion. However, the endobronchial route of transfection pro-
vides the possibility of repeat administration in an effort to
have a lasting effect on graft rejection.
In conclusion, the present study demonstrated that lipid-
mediated ex vivo viral IL10 gene transfer into rat lung allo-
grafts improved graft gas exchange, reduced histologic
rejection score, downregulated graft IL-2 mRNA expres-
sion, and reduced exhaled NO levels by postoperative day 5
in a model of rat lung allotransplantation. These data strong-
ly support the notion that lipid-mediated graft viral IL10
gene transfer may be an effective immunosuppressive strat-
egy that may overcome acute lung allograft rejection.
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